At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
-
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
-
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
-
Doctors are assessing a new photodynamic therapy (PDT) for prostate cancer that has not spread beyond the prostate. This treatment is performed in an operating room while you are under general anesthesia.
-
Researchers want to find the best dose of IPH6501 that can be used safely in people with non-Hodgkin lymphoma (NHL). The people in this study have NHL that returned or keeps growing after treatment and makes a protein called CD20. The types of lymphoma eligible for this study include:
-
Researchers are comparing two new combination drug treatments with the standard therapy for multiple myeloma. The people in this study have multiple myeloma that is newly diagnosed. In addition, they cannot have an autologous stem cell transplant with high-dose chemotherapy.
-
The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).
- A Phase 3 Study Assessing Dara-VCD Chemotherapy Alone or With a Stem Cell Transplant for People With Newly Diagnosed AL Amyloidosis
Full Title A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (S2213) (CIRB)
Purpose
Researchers are comparing combination chemotherapy alone or with a stem cell transplant for people with amyloid light chain (AL) amyloidosis. The people in this study have newly diagnosed AL amyloidosis. The chemotherapy includes daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD).
If you join this study, you will be randomly assigned to get one of these treatments:
- Dara-VCD alone.
- Dara-VCD followed by a stem cell transplant with melphalan. Giving melphalan before a stem cell transplant helps kill cancer cells and makes room for new blood-forming cells to grow.
A stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in people with newly diagnosed AL amyloidosis.
Who Can Join
To join this study, there are a few conditions. You must:
- Have newly diagnosed AL amyloidosis.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Heather Landau’s office at 646-608-3740.
Protocol
25-107Phase
Phase III (phase 3)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06022939ClinicalTrials.gov
-
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
-
Researchers want to find the best schedule for giving a new vaccine to people with neuroblastoma. The people in this study have neuroblastoma that is in remission (no signs of cancer). In addition, their cancers have a strong chance of coming back (high risk). The vaccine is given with a naturally occurring substance called beta-glucan.